SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab gains on receiving approval to increase FII investment limits up to 74%

05 Aug 2013 Evaluate

Strides Arcolab is currently trading at Rs. 716.00, up by 21.30 points or 3.07% from its previous closing of Rs. 694.70 on the BSE.

The scrip opened at Rs. 700.00 and has touched a high and low of Rs. 729.00 and Rs. 696.00 respectively. So far 7,885 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1224.90 on 05-Dec-2012 and a 52 week low of Rs. 552.65 on 01-Aug-2013.

Last one week high and low of the scrip stood at Rs. 724.00 and Rs. 552.65 respectively. The current market cap of the company is Rs. 4,227.00 crore.

The promoters holding in the company stood at 27.39% while Institutions and Non-Institutions held 59.81% and 12.80% respectively.

Strides Arcolab has received an approval to increase the Foreign Institutional Investors (FII) investment limit in the company. FII’s can now invest up to 74% of the paid up equity share capital of the company under the Portfolio Investment Scheme. The current FII holding in the company is 52%.

The shareholders of the company at their Extraordinary General Meeting held on August 03, 2013, have approved for the same. As required under the FEMA Regulation, the company has made necessary intimation to the Reserve Bank of India confirming the shareholders’ approval for the increased FII investment limit.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×